The patent dispute over ‘Entresto (sacubitril/valsartan),’ a chronic heart failure treatment with an annual prescription of more than KRW 40 billion, has been ongoing for over 2 years now.

Novartis, the company that owns the original drug, is actively pursuing a defense strategy against generic companies' patent challenges. Novartis appealed after losing the 1st trial, and three cases are being tried in the second trial. Some of the results are expected to be pronounced next month.

According to industry sources on the 8th, Novartis filed a trial revocation litigation against Hanmi Pharm and Elyson Pharm regarding Entresto’s salt·hydrate patent (10-1549318). After losing to generic co